Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials
Marthe Kirkesæther Brun, Johanna Elin Gehin, K. H. Bjørlykke, David J. Warren, Rolf Anton Klaasen, Joseph Sexton, Øystein Sandanger, Tore K Kvien, Cato Mørk, Jørgen Jahnsen, Nils Bolstad, Kristin Kaasen Jørgensen, Espen A. Haavardsholm, Guro Løvik Goll, Silje Watterdal Syversen
Topics & Concepts
MedicineInfliximabInternal medicineDiscontinuationDosingPlaceboTherapeutic drug monitoringClinical trialRandomized controlled trialDrugPharmacologyDiseasePharmacokineticsPathologyAlternative medicineBiosimilars and Bioanalytical MethodsRheumatoid Arthritis Research and TherapiesInflammatory Bowel Disease